Type 2 diabetes, formerly referred to as non-insulin-dependent or adult-onset diabetes, is a chronic medical condition caused by insulin resistance, inadequate insulin secretion, or a combination of both.
This method is relatively convenient and less expensive than OGTT. 4 For an FPG test, a venous blood sample is drawn in the physician's office following a 12-hour overnight fast. This specimen is analyzed in a core laboratory. According to the 2003 ADA consensus guidelines, an FPG level between 100mg/dl (5.5mmol/l) and 125mg/dl (6.9mmol/l)is defined as IFG, or pre-diabetes. For an OGTT, a venous blood sample is also drawn in the physician's office after a 12-hour overnight fast. The patient is administered a 75g oral dose of glucose. The patient must remain in the physician's office until a second venous blood sample is collected two hours after the glucose dose. Both fasting and two-hour samples are analyzed in a core laboratory. If the first result falls in the impaired fasting glucose range, or the two-hour post-dose result lies between 140mg/dl (7.8mmol/l) and 199mg/dl (11.1mmol/l), these results are indicative of IGT, or pre-diabetes. As mentioned, FPG alone is commonly used to screen for diabetes, but an OGTT more reliably detects diabetes.
The same can be said for the detection of pre-diabetes. Studies have demonstrated that FPG alone detects only 30-65% of patients with diabetes, while OGTT detects around 90%. 3, 5 For this reason, OGTT is still considered a standard method for diagnosis of diabetes.
Pre-diabetes and the Benefits of Intervention
The importance of identifying diabetes and pre-diabetes is related to the risk of developing complications from elevated blood glucose levels. 
Laboratory Testing
To date, the measurement of fasting plasma glucose levels on venous blood samples has been the standard means of diagnosing diabetes. An abnormal fasting plasma glucose test that is followed by an OGTT aids in the discrimination of IFG, IGT, or overt diabetes. In recent years, great advances have been made in the field of point-of-care testing (POCT).
The ability to perform tests and obtain results faster at the point of care
(POC) has been especially significant in the monitoring and management of diabetes. Patients and practitioners are able to check a patient's blood glucose rapidly at the bedside, at home, or in the doctor's office. However, POC blood glucose monitoring is especially susceptible to errors due to pre-analytical, analytical, and postanalytical effects, 15 given that a range of clinical staff and patients without laboratory experience are performing the test. It is this rise in the use of POCT that has led to the question of whether POCT can be used in the diagnosis of diabetes. Before POC glucose meters can be used in the diagnosis of diabetes, the device results should match the technical performance of any currently accepted diagnostic tool.
One of the most important technical criteria is the accuracy or agreement between glucose meter results and the laboratory glucose levels analyzed in a centralized laboratory. The ADA recommends that glucose meter results agree with a central laboratory within ±5%, 100%
of the time. This goal has been difficult to achieve because of the many factors that influence POCT. 17 The study only included six centers in the US, three in Europe, and one in Cameroon. Another center in Asia was eliminated from the data due to improper specimen storage.
Participants were between 18 and 70 years of age, but did not include children or pregnant women. 16, 17 The study was also limited in terms of the number of ethnic groups with a high prevalence of diabetes, such as African-Americans, American-Indians and Eskimos. An argument could be made as to whether these factors are relevant to the hemoglobin/ average glucose relationship, since glucose-hemoglobin binding is nonenzymatic. However, very little research has been undertaken on the utility of HbA 1c outside its traditional use in monitoring dietary and lifestyle compliance and insulin management. All current treatment and diagnostic recommendations are based on the Diabetes Control and Complications Trial (DCCT), which examined direct blood glucose levels, not HbA 1c . 6, 7, 17 Just this year, the ADA commissioned an International Expert Committee on diabetes to re-examine the concept of HbA 1c for the diagnosis of diabetes. Taking into consideration long-term glycemic levels and the timing of onset of diabetic complications, the committee was able to set the diagnostic threshold for diabetes at an HbA 1c percentage of ≥6.5%
and a range of 6.0 to <6.5% for pre-diabetes. These numbers, while not being absolute dividing lines, are sufficiently sensitive and specific to identify individuals at risk for developing diabetic complications and could therefore be used to diagnose patients as having diabetes or prediabetes. 18 Along with setting these thresholds, the authors identified a 
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